Top Story

Higher copayments linked to therapy nonadherence, discontinuation among women with breast cancer

November 26, 2014

Women with early-stage breast cancer who used generic aromatase inhibitors appeared more likely to continue and adhere to their hormone therapy regimens than women who used brand-name agents with higher co-payments, according to study results.

Dawn L. Hershman, MD, MS, associate professor of medicine at Columbia University Medical Center, and colleagues obtained pharmacy and claims data from OptumInsight to identify 5,511 women aged older than 50 years who used aromatase inhibitors for early-stage breast cancer between Jan. 1, 2007, and Dec. 31, 2012.

Peter J. Mazzone, MD, FCCP Meeting News Coverage

Serum metabolites may serve as biomarker for early lung cancer detection

November 26, 2014
Serum metabolite profiles significantly differed between patients with stage I to III non–small cell lung cancer and at-risk adults without lung cancer, a finding…
In the Journals

Total-body photography may reduce melanoma worry in patients with atypical mole syndrome

November 26, 2014
The use of total-body digital photography may reduce concerns about melanoma development among patients with atypical mole syndrome, according to study results.Molly S
In the Journals

Researchers identify factors associated with hypocalcemia after thyroidectomy

November 25, 2014
A low postoperative intact parathyroid hormone level, female gender and presence of malignant neoplasm all independently predicted hypocalcemia after total…
In the Journals

Combined-modality treatment effective for muscle-invasive bladder cancer

November 25, 2014
Patients with muscle-invasive bladder cancer who underwent bladder-preserving combined-modality therapy experienced disease-specific survival comparable to that…
More News Headlines »
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
thumbnail for video 3886443649001

Risk stratification guidelines help determine treatment for thyroid cancer

November 11, 2014
Fabian Pitoia, MD,  head of the thyroid section of the division of endocrinology at the Hospital de Clinicas of…
More »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »